Tech Company Financing Transactions
ImpriMed Funding Round
ImpriMed, based in Palo Alto, secured $8 million from HG Initiative, BonAngels Venture Partners and Draper Associates.
Transaction Overview
Company Name
Announced On
4/16/2021
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
Proceeds Purpose
The company plans to use the new funding to develop additional prediction models for their current target patients in canine blood cancers, scale up their customer network, and expand pipelines to other types of cancers in dogs and cats.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4030 Fabian Way
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Undisclosed
Website
Email Address
Overview
ImpriMed develops a personalized drug testing service to look into drug responses of pet patient's live cancer cells before treatment. The company helps veterinary oncologists decide a final treatment regimen based on data-driven prediction of response success in each individual patient body and builds up a patient-derived database.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sungwon Lim
Co-Founder
Mainak Chowdhury
Co-Founder
Jamin Koo
Co-Founder
David Kurtz
Co-Founder
Hye Lee
VP - Operations
Mary Ocnean
Browse more venture capital transactions:
Prev: 4/16/2021: Persefoni venture capital transaction
Next: 4/17/2021: Level venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs